Expert Illustrations & Commentaries: Exploring the Role of BTK Inhibition in the Treatment of Multiple Sclerosis

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from Sanofi Genzyme.

Credit Available

• Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
• Nurses — 1.0 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity is directed toward neurologists, and other health care professionals who treat patients with multiple sclerosis.

Activity Overview

This activity is a video-based program in which 2 experts discuss the etiology and management of multiple sclerosis (MS). In this activity, the faculty focus on the pathophysiology of MS as it relates to Bruton’s tyrosine kinase (BTK), as well as clinical trial data on the efficacy and safety of novel BTK inhibitors in MS treatment. Their discussion is enriched with the use of video animations to illustrate MS pathophysiology, as well as the mechanism of action of BTK inhibitors in MS. The use of these animated segments helps make somewhat complicated subject matter more easily understood. This unique format is designed to help clinicians identify best practices in the diagnosis and management of MS and to improve outcomes for their patients with this disease.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Discuss the inflammatory pathophysiology of MS as related to BTK
• Describe the safety and efficacy of BTK inhibitors in the management of patients with relapsed-remitting and progressive forms of MS
• Incorporate recent and emerging data into case-based treatment strategies for MS based on patient-specific needs

 

Faculty

 

Physician Accreditation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit Designation

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Disclosures of Conflicts of Interest

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.

Claire S. Riley, MD

• Consultant: Genentech

 

Stephen Krieger, MD, FAAN

• Grant/Research Support: Biogen, Novartis Pharmaceuticals
• Consultant: Biogen, EMD Serono, Genentech, Sanofi Genzyme, Mallinckrodt Pharmaceuticals, MedDay Pharmaceuticals, Novartis Pharmaceuticals, Octave Bioscience, Teva Pharmaceuticals, TG Therapeutics
• Speakers’ Bureau: Nonpromotional Speaking: Biogen, EMD Serono, Genentech, Novartis Pharmaceuticals

 

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Instructions for Participation and Credit

1. Complete the activity (including pre- and post-activity assessments).
2. Answer the evaluation questions.
3. Request credit using the drop-down menu.

You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.